Side-by-side · Research reference

MOTS-cvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/68 cited

BPhase 3HUMAN-REVIEWED9/42 cited

MOTS-c

Mitokine · Mitochondria-Encoded

5–10 mgWeekly doseLee 2015

AnimalEvidence levelLee 2015 Reynolds 2021

Min–hrsHalf-life

SQ · Variable · 2–3×/week

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

MOTS-c

VIP

Primary target

Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Folate cycle inhibition → ↑AICAR → AMPK phosphorylation → PGC-1α upregulationLee 2015 Kim 2018

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

Stress-responsive, AMPK-dependent nuclear translocationKim 2018

Yes — exogenous VIP acts as physiological agonist

Origin

Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

MOTS-c

VIP

Standard dose

5–10 mg / weekLee 2015

Experimental, extrapolated from animal data. No human RCT-derived dose.

—

Frequency

2–3× per week

Short half-life may necessitate more frequent dosing for saturation.

—

Lower / starter dose

2.5–5 mg / week

Recommended due to limited human data.

—

Evidence basis

Animal + anecdotalLee 2015 Reynolds 2021 A first-in-human phase 1 study 2021

Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Duration

4–12 weeks (experimental)

Optimal cycle length unknown.

—

Reconstitution

Bacteriostatic water, 1–2 mL

10 mg/mL at 1 mL.

Lyophilized powder reconstituted with sterile diluent per protocol

Timing

Pre-workout or fasted state preferred

Activity-context amplifies AMPK response.

—

Half-life

Minutes to hours (estimated)

Systemically unstable; native MOTS-c PK in humans not fully characterised.

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

03Metabolic / Fat Loss Evidence

Parameter

MOTS-c

VIP

Primary fat target

Diet-induced / metabolic obesity; systemic fat utilization

—

Quantified reduction

Significant HFD fat gain ↓Lee 2015

Murine models, dose-dependent (5 & 15 mg/kg).

—

IGF-1 impact

No direct IGF-1 pathway; AMPK-mediated

—

Effect on lean mass

High dose significantly ↑ lean mass in mice

—

Insulin sensitivity

Reversed HFD insulin resistance in 7 days (mice)Lee 2015

—

Triglycerides

AMPK-driven FA oxidation suggests TG benefit (not directly measured)

—

Glucose metabolism

Improved glucose tolerance; GLUT4 upregulationLee 2015

—

Effect reversibility

Unknown — no long-term follow-up data

—

Context dependency

No effect in normal-chow mice; requires metabolic stressReynolds 2021

—

Key publication

Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015 Reynolds 2021 Kim 2018

—

04Side Effects & Safety

Parameter

MOTS-c

VIP

Injection site reaction

Mild irritation (reported)

—

Fluid retention / Edema

Not reported

—

Glucose intolerance

Improves glucose toleranceLee 2015

—

Cardiovascular

Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats

—

Cancer risk

Contradictory data — some models suggest pro-proliferative effects

—

CNS / Neurological

Insomnia, headache (anecdotal reports)

—

GI symptoms

Nausea, stomach discomfort (reported)

Nausea, diarrhea (VIP is endogenous GI peptide)

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Evidence quality

Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

MOTS-c

·Pregnancy / breastfeeding (insufficient data)

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

MOTS-c

·Active cancer or cancer predisposition
·AMPK pathway deficiency (efficacy nullified)
·Use with cancer-promoting medications (theoretical)

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

MOTS-c

VIP

1. Reconstitution

Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Injection site

Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Needle

27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.

06Stack Synergy

MOTS-c

+ Ipamorelin

Moderate

View Ipamorelin →

MOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.

MOTS-c: 5 mg SQ · pre-workout (2–3×/wk)
Ipamorelin: 200–300 mcg SQ · pre-sleep (daily)
Primary benefit: Metabolic flexibility + GH recovery + ROS reduction

VIP

— no documented stacks